AstraZeneca 4Q08

AstraZeneca

4Q Revenues: $8.2 billion (flat)

4Q Earnings: $1.3 billion (flat)

FY Revenues: $31.6 billion (+7%)

FY Earnings: $6.1 billion (+9%)

Comments: Nexium sales were $1.3 billion in the quarter (+6%) but down 2% for the year to $5.2 billion. Losec/Prilosec sales were down 11% to $264 million in the quarter and down 14% to $1.1 billion for the year due to generic competition. Crestor sales were $987 million in the quarter (+30%) and $3.6 billion for the year (+26%). Seloken /Toprol-XL sales were $207 million (+2%) in the quarter, but down 46% for the year to $807 million, impacted by generic competition. Symbicort sales were $514 million in the quarter (+29%) and $2.0 billion for the year (+22%). Pulmicort sales were down 10% in the quarter to $397 million due to the “at risk” launch of Teva’s generic in November. Pulmicort sales were flat for the year. Seroquel sales were $1.2 billion in the quarter (+10%) and $4.5 billion for the year (+9%). R&D expenses were $1.3 billion in the quarter (-5%) and flat for the year at $5.2 billion.